Mostrar el registro sencillo del ítem

dc.contributor.authorJankovic, Radmila
dc.contributor.authorGoncalves, Helena J.
dc.contributor.authorCavic, Milena
dc.contributor.authorClemente, Carla
dc.contributor.authorLind, Michael
dc.contributor.authorMurillo Carrasco, Alexis
dc.contributor.authorNadifi, Selama
dc.contributor.authorKhyatti, Meriem
dc.contributor.authorAdebambo, Tumininu
dc.contributor.authorEgamberdiev, Dilshod
dc.date.accessioned2020-05-28T18:17:21Z
dc.date.available2020-05-28T18:17:21Z
dc.date.issued2019
dc.identifier.citationJankovic R., Goncalves HJ., Cavic M. Clemente C., Lind M., Murillo A., et al. LungCARD - Report on worldwide research and clinical practices related to lung cancer. JBuon. 2019;24(1): 11‐19.es_PE
dc.identifier.issn1107-0625 (Impreso)
dc.identifier.issn2241-6293 (Digital)
dc.identifier.otherhttps://jbuon.com/24-1/
dc.identifier.urihttps://hdl.handle.net/20.500.12727/6113
dc.description.abstractPurpose: The management of advanced lung cancer has evolved tremendously over the past two decades. Increasing understanding of the molecular changes that drive tumor progression has transformed the treatment of this disease. Nevertheless, various countries differ in the degree of implementation of genetic tests and the availability of innovative drugs. The LungCARD consortium created a questionnaire to collect information about the local research and clinical practices related to lung cancer diagnosis and therapy. Methods: A survey composed of 37 questions related to specific lung cancer pharmacogenomics and therapy, was distributed among 18 countries. Results: All together 36 responses were gathered, answered mainly by clinicians. The majority attends 50-200 cancer cases per month, 20-50% of all cancer cases are lung cancer patients, and more than 80% are with non-small-cell lung cancer (NSCLC). Targeted therapy is applied to 50% on average of all NSCLC patients. Forty five percent of participating medical oncologists are treating their patients with immunotherapy. More than 90% of the respondents are guided by results of genetic tests in introducing targeted treatment. As expected, the majority orders EGFR gene testing (85%), followed by ALK (58%) and KRAS testing (32%). Almost all (96%) agreed that more biomarkers should be included in routine genetic testing (ROS1, anti-PDL1, KRAS, MET, HER2, BRAF...), and that blood test is useful in pharmacogenomic testing. Conclusion: There is a great variation between countries with respect to all discussed topics. However, the majority recognized a necessity of introducing next generation sequencing (NGS)-based diagnostics and potential of testing from blood. The biggest problem in the treatment of NSCLC is still an access to innovative drugs.es_PE
dc.description.sponsorshipEuropean Union’s Horizon 2020 research and innovation programme under grant agreement No 734790 Project Number: 734790es_PE
dc.format.extentpp. 11-19es_PE
dc.language.isospaes_PE
dc.publisherBAKIS Productions LTDes_PE
dc.relation.ispartofseriesJournal of Boun;vol. 24, no. 1
dc.relation.urihttps://pubmed.ncbi.nlm.nih.gov/30941946/es_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es_PE
dc.sourceRepositorio Académico USMPes_PE
dc.sourceUniversidad San Martín de Porres - USMPes_PE
dc.subjectBiomarcadoreses_PE
dc.subjectEncuestas y cuestionarioses_PE
dc.subjectCarcinoma de pulmón de células no pequeñases_PE
dc.subjectPronósticoes_PE
dc.titleLungCARD – Report on worldwide research and clinical practices related to lung canceres_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
thesis.degree.nameMedicina Humana
thesis.degree.grantorUniversidad de San Martín de Porres. Facultad de Medicina Humana
thesis.degree.disciplineMedicina


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/openAccess
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess